Brought to you by 
EyeTech Pharmaceuticals gets rights to Gilead's NX 1838
18 May 2000
Executive Summary
Gilead Sciences (infectious diseases and cancer) granted EyeTech (eye disease therapeutics) exclusive worldwide rights for all therapeutic applications to its aptamer NX 1838, which inhibits the vascular endothelial growth factor involved in the wet form of age-related macular degeneration and diabetic retinopathy.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
EyeTech Pharmaceuticals gets rights to Gilead's NX 1838
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice